Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1960P - Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models

Date

17 Sep 2020

Session

E-Poster Display

Topics

Translational Research

Tumour Site

Presenters

Paul McSheehy

Citation

Annals of Oncology (2020) 31 (suppl_4): S1034-S1051. 10.1016/annonc/annonc294

Authors

P. McSheehy1, J. Guo2, K. Beebe2, J.R. Eisner2, S. Anderson3, S. Braun3, M. Engelhardt3, L. Kellenberger1, H. Lane1, M. Milburn2

Author affiliations

  • 1 Research, Basilea Pharmaceutica International Ltd., 4058 - Basel/CH
  • 2 Research, GeneCentric Therapeutics, Inc., 27713 - Durham/US
  • 3 Development, Basilea Pharmaceutica International Ltd., 4058 - Basel/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1960P

Background

FGFR-inhibitors (FGFRi) show antitumor activity in cancers driven by FGFR genetic alterations (GA). Derazantinib (DZB) is in Phase 2 development for UC (NCT04045613), erdafitinib (ERDA) is FDA approved for advanced UC with FGFR GA. Clinical safety profiles of different FGFRi have not been compared head-to-head. Non-controlled studies suggest adverse events (AE), such as hyperphosphatemia, gastrointestinal AE, fatigue and dry eye, as common FGFRi class effects, while absence or lower rates of drug-related retinopathy, stomatitis, hand-foot-syndrome or nail toxicity were reported for DZB vs ERDA. Here we report whole transcriptome changes for DZB and ERDA in various safety relevant target tissues in nude mice bearing UC-PDX.

Methods

DZB (75 mg/kg) or ERDA (30 mg/kg) at optimal efficacious doses, or vehicle, was given daily PO (21 d) to mice bearing UC PDX (BL3479; n=3/group). Flash frozen target tissues (eye, foot/nail, cheek, lung, liver) underwent RNA sequencing (SureSelect XT RNA, Agilent) to compare transcriptome profiles (expression difference vs vehicle) and assess shared or compound-specific changes.

Results

Shared gene expression changes were consistent with canonical FGFR biology; including genes involved in tissue repair or remodeling. DZB-specific changes included keratin gene downregulation (lung) and collagen/extracellular matrix suppression (foot/nail). ERDA-specific changes included downregulation in crystallin genes (eye) potentially associated with retinal toxicity, and increase in oral epithelium stress, turnover/repair genes (cheek) potentially associated with mucositis.

Conclusions

Shared gene expression changes observed with DZB and ERDA reflect canonical FGFR biology and shared AEs. Several compound-specific gene expression changes map to reported AE profile differences between ERDA and DZB, e.g. retinal toxicity and mucositis. Molecular dissection of target tissues via RNA sequencing may provide a new tool to interpret shared target biology and compound-specific toxicity profiles between different FGFRi.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Basilea Pharmaceutica International Ltd.

Funding

Basilea Pharmaceutica International Ltd.

Disclosure

P. McSheehy, S. Anderson, S. Braun, M. Engelhardt, L. Kellenberger, H. Lane: Shareholder/Stockholder/Stock options, Full/Part-time employment: Basilea Pharmaceutica International Ltd. J. Guo, K. Beebe, J.R. Eisner, M. Milburn: Shareholder/Stockholder/Stock options, Full/Part-time employment: GeneCentric Therapeutics, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.